Alidousty, Christina, Duerbaum, Nicolai, Wagener-Ryczek, Svenja, Baar, Till ORCID: 0000-0002-6744-1463, Martelotto, Luciano G., Heydt, Carina, Siemanowski, Janna, Holz, Barbara, Binot, Elke, Fassunke, Jana, Merkelbach-Bruse, Sabine, Wolf, Juergen, Kron, Anna, Buettner, Reinhard and Schultheis, Anne M. . Prevalence and potential biological role of TERT amplifications in ALK translocated adenocarcinoma of the lung. Histopathology. HOBOKEN: WILEY. ISSN 1365-2559

Full text not available from this repository.

Abstract

Aims The advent of specific ALK-targeting drugs has radically changed the outcome of patients with ALK translocated non-small-cell lung cancer (NSCLC). However, emerging resistance to treatment with ALK inhibitors in these patients remains a major concern. In previous studies, we analysed two ALK+ patient cohorts (TP53 wild-type/TP53 mutated) in terms of copy number alterations. All patients belonging to the TP53 wild-type group had mainly genetically stable genomes, with one exception showing chromosomal instability and amplifications of several gene loci, including TERT. Here, we aimed to determine the prevalence of TERT amplifications in these ALK+ lung cancer patients by analysing an independent cohort of 109 ALK translocated cases. We further analysed the copy numbers of numerous cancer-relevant genes and other genetic aberrations. Methods and results The prevalence of TERT amplifications was determined by means of FISH analyses. Copy numbers of 87 cancer-relevant genes were determined by NanoString nCounter(R) technology, FoundationOne(R) and lung-specific NGS panels in some of these TERT-amplified samples, and clinical data on patients with TERT-amplified tumours were collected. Our data revealed that five (4.6%) of all 109 analysed ALK+ patients harboured amplification of TERT and that these patients had genetically unstable genomes. Conclusions Our preliminary study shows that ALK+ adenocarcinomas should be evaluated in the context of their genomic background in order to more clearly understand and predict patients' individual course of disease.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Alidousty, ChristinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Duerbaum, NicolaiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wagener-Ryczek, SvenjaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Baar, TillUNSPECIFIEDorcid.org/0000-0002-6744-1463UNSPECIFIED
Martelotto, Luciano G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heydt, CarinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Siemanowski, JannaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Holz, BarbaraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Binot, ElkeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fassunke, JanaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Merkelbach-Bruse, SabineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wolf, JuergenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kron, AnnaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Buettner, ReinhardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schultheis, Anne M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-311150
DOI: 10.1111/his.14256
Journal or Publication Title: Histopathology
Publisher: WILEY
Place of Publication: HOBOKEN
ISSN: 1365-2559
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
PROMOTER MUTATIONS; CHROMOTHRIPSIS; GENE; NEUROBLASTOMA; REARRANGEMENTS; ACTIVATION; MECHANISM; FREQUENT; PROTEIN; MODELMultiple languages
Cell Biology; PathologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/31115

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item